In a chronic myeloid leukemia stem cell model, persistent application of CDK4/6 inhibitor resulted in CDK6-induced p53 mutation via a transcriptional regulation mechanism (27). This evidence concerns the gene CDK6 and chronic myelogenous leukemia, BCR-ABL1 positive.